TY - JOUR
T1 - Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia
T2 - Short- and long-term outcomes
AU - Frankfurt, Olga
AU - Ma, Shuo
AU - Gordon, Leo
AU - Winter, Jane N.
AU - Horowitz, Jeanne M.
AU - Rademaker, Alfred
AU - Weitner, Bing Bing
AU - Peterson, Loann C.
AU - Altman, Jessica K.
AU - Tallman, Martin S.
AU - Petrich, Adam
AU - Rosen, Steven T.
N1 - Publisher Copyright:
© 2014 Informa UK, Ltd.
PY - 2015/2/1
Y1 - 2015/2/1
N2 - We investigated the safety, efficacy, and long-term outcomes of alemtuzumab and rituximab (AR) combination therapy in previously untreated patients with CLL. Thirty patients, ages 28-80 years, 47% older than 60 years, 90% Rai clinical stages II-IV, and 67% without favorable cytogenetics received AR. Based on the NCI-WG 1996 criteria, OR was 100%, with 60% CR. With CT scans OR was 70%, with 23% CR, 47% PR, and 30% SD. Sixty-seven percent of patients showed no evidence of MRD in the bone marrow by 6-color flow cytometry. Median PFS, TFS, and 5-year OS were 24.4, 50.7 months, and 80%, respectively. Grade 3/4 neutropenia and thrombocytopenia were reported in 30% and 7% of patients, respectively. CMV reactivation, asymptomatic in all but one patient, occurred in 8 patients. Immunotherapy with alemtuzumab and rituximab results in robust responses and long asymptomatic therapy-free intervals. It is well tolerated with infrequent, predictable, and easily managed complications.
AB - We investigated the safety, efficacy, and long-term outcomes of alemtuzumab and rituximab (AR) combination therapy in previously untreated patients with CLL. Thirty patients, ages 28-80 years, 47% older than 60 years, 90% Rai clinical stages II-IV, and 67% without favorable cytogenetics received AR. Based on the NCI-WG 1996 criteria, OR was 100%, with 60% CR. With CT scans OR was 70%, with 23% CR, 47% PR, and 30% SD. Sixty-seven percent of patients showed no evidence of MRD in the bone marrow by 6-color flow cytometry. Median PFS, TFS, and 5-year OS were 24.4, 50.7 months, and 80%, respectively. Grade 3/4 neutropenia and thrombocytopenia were reported in 30% and 7% of patients, respectively. CMV reactivation, asymptomatic in all but one patient, occurred in 8 patients. Immunotherapy with alemtuzumab and rituximab results in robust responses and long asymptomatic therapy-free intervals. It is well tolerated with infrequent, predictable, and easily managed complications.
KW - Alemtuzumab
KW - CLL
KW - Immunotherapy
KW - Rituximab
UR - http://www.scopus.com/inward/record.url?scp=84923924098&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84923924098&partnerID=8YFLogxK
U2 - 10.3109/10428194.2014.910654
DO - 10.3109/10428194.2014.910654
M3 - Article
C2 - 24707943
AN - SCOPUS:84923924098
SN - 1042-8194
VL - 56
SP - 315
EP - 323
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 2
ER -
